OBSTETRIC-FETAL PHARMACOLOGY RESEARCH UNITS NETWORK

该子项目是利用 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得主要资金， 因此可以在其他CRISP条目中表示。列出的机构是 中心，不一定是研究者的机构。 德克萨斯大学医学分支（UTMB）有能力作为产科-胎儿药理学研究单位（OPRU）网络的成员积极参与。加里汉金斯，医学博士，作为PI，是负责拟议的临床试验使用降糖药物治疗糖尿病在怀孕期间。他在几项NIH多中心试验中拥有丰富的经验，例如，非整倍体风险的早期和中期评估（FASTER），子宫硫酸镁研究（BEAM）的有益作用和阴道超声环扎试验。Hankins博士通过参与UTMB的区域妇幼保健计划（RMCHP）成功招募和留住了患者。所有RMCHP诊所都遵循由汉金斯博士领导的母胎医学部门制定的协议。每年有12 000多名孕妇在RMCHP诊所系统内接受护理，其中约7 000人在UTMB分娩。药理学/药代动力学（PK）合作研究者Mahmoud S. Ahmed博士在研究中利用人类胎盘和衍生制剂方面拥有超过25年的专业知识。Ahmed博士是胎盘受体、其天然配体和介导反应以及滋养层组织释放hCG机制的实验室先驱研究者。他们研究了体外和体内长期给予阿片类药物对胎盘生理学和母婴结局的影响。利用胎盘小叶的双重灌注，他们证明了外排蛋白和胎盘代谢酶对阿片类药物胎盘转运PK的影响。他们确定胎盘芳香化酶是一种药物代谢酶，并正在研究其多态性。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The University of Texas Medical Branch (UTMB) has the capability to participate actively as a member of the Obstetric-Fetal Pharmacology Research Units (OPRU) Network. Gary Hankins, MD, as PI, is responsible for the proposed clinical trial on the use of hypoglycemic drugs in the treatment of diabetes during pregnancy. He has extensive experience within several NIH multicenter trials, eg, First and Second Trimester Evaluation of Risk of Aneuploidy (FASTER), Beneficial Effects of Antenatal Magnesium Sulfate Study (BEAM), and the Vaginal Ultrasound Cerclage Trial. Dr. Hankins has achieved successful patient recruitment and retention by involvement with UTMB's Regional Maternal & Child Health Program (RMCHP). All RMCHP clinics follow protocols established by the Maternal-Fetal Medicine division, headed by Dr. Hankins. Over 12,000 pregnant women are cared for annually within the RMCHP clinic system, approximately 7,000 of whom deliver at UTMB. The Pharmacology/Pharmacokinetics (PK) Co-Investigator, Mahmoud S. Ahmed, PhD, has over 25 years of expertise in utilizing human placenta and derived preparations in his investigations. Dr. Ahmed is a laboratory-pioneered investigator in placental receptors, their natural ligands and mediated responses, as well as the mechanism of hCG release from trophoblast tissue. They investigated the effects of in vitro and in vivo chronic administration of opiates on placental physiology and maternal-neonatal outcome. Utilizing dual perfusion of placental lobule, they demonstrated the influence of efflux protein and placental metabolic [enzymes on the PK for placental transfer of opiates. They identified placental aromatase as a drug-metabolizing enzyme and are investigating its polymorphism.